| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VIVOS Aktie jetzt für 0€ handeln | |||||
| 06.07. | Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel Precision Radionuclide Therapy | 393 | GlobeNewswire (Europe) | Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased... ► Artikel lesen | |
| 11.06. | Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet Manufacturing | 185 | GlobeNewswire (Europe) | Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased... ► Artikel lesen | |
| 05.06. | Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel Precision Radionuclide Therapy | 1 | GlobeNewswire (USA) | ||
| 14.05. | VIVOS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.02. | Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites | 319 | GlobeNewswire (Europe) | Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel Radionuclide Therapy (PRnT) is preparing to open two new production... ► Artikel lesen | |
| 10.02. | Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel Precision Radionuclide Therapy | 318 | GlobeNewswire (Europe) | Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) with its innovative RadioGel technology, today... ► Artikel lesen | |
| 03.02. | Vivos Inc.: Vivos Inc Updates Human Therapy Progress in India | 1 | GlobeNewswire (USA) | ||
| 28.01. | Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL Trademark Approvals | 1 | GlobeNewswire (USA) | ||
| 06.11.25 | Vivos Inc. Issues Shareholder Update Letter | 250 | GlobeNewswire (Europe) | Kennewick, WA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) - The Company continues to prioritize securing FDA Investigational Device Exemption (IDE) approval to initiate human clinical... ► Artikel lesen | |
| 29.10.25 | Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics | 246 | GlobeNewswire (Europe) | Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology... ► Artikel lesen | |
| 29.09.25 | Vivos Inc.: Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India | 225 | GlobeNewswire (Europe) | Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name... ► Artikel lesen | |
| 08.09.25 | Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy | 181 | GlobeNewswire (Europe) | Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for... ► Artikel lesen | |
| 14.08.25 | Vivos Inc.: Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA | 234 | GlobeNewswire (Europe) | Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission. We are now focused on addressing... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 41,730 | -0,24 % | Fresenius bestätigt Ziele nach Gesetzesverabschiedung | DJ Fresenius bestätigt Ziele nach Gesetzesverabschiedung
DOW JONES--Fresenius hat nach Verabschiedung des GKV-Beitragssatzstabilisierungsgesetzes seine Prognose für das Gesamtjahr bestätigt.
... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 70,62 | +3,61 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P MidCap 400 and Karman Holdings to Join S&P SmallCap 600 | NEW YORK, July 14, 2026 /PRNewswire/ -- S&P SmallCap 600 constituent BrightSpring Health Services Inc. (NASD: BTSG) will replace Chart Industries Inc. (NYSE: GTLS)... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 35,120 | -0,11 % | ANALYSE-FLASH: Berenberg senkt Siemens Healthineers auf 'Hold' | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Siemens Healthineers von 54 auf 39 Euro gesenkt und die Aktien von "Buy" auf "Hold" abgestuft. Bei den Faktoren, die dem Medizintechnikkonzern... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,240 | +0,45 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 11,580 | +2,57 % | LifeStance Health Group, Inc.: LifeStance Reports First Quarter 2026 Results | SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results... ► Artikel lesen | |
| GENEDX | 63,48 | 0,00 % | Piper Sandler raises GeneDx stock price target on coverage policy | ||
| CARL ZEISS MEDITEC | 29,300 | -2,33 % | DEUTSCHE BANK RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Carl Zeiss Meditec von 30 auf 28 Euro gesenkt und die Einstufung auf "Hold" belassen. In einem am Dienstag vorliegenden Ausblick... ► Artikel lesen | |
| BILLIONTOONE | 130,18 | +1,56 % | BillionToOne, Inc.: BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| ALIGNMENT HEALTHCARE | 20,580 | 0,00 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 19,230 | 0,00 % | PROCEPT BioRobotics to Report Second Quarter 2026 Financial Results on August 4th, 2026 | ||
| PRIVIA HEALTH GROUP | 26,870 | -1,29 % | Privia Health Group, Inc.: Privia Health Reports First Quarter 2026 Financial Results | Strong First Quarter Performance and Operating ExecutionReiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq:... ► Artikel lesen | |
| INTUITIVE SURGICAL | 302,00 | -14,19 % | Opening Bell: IBM, Netflix, Intuitive Surgical, Alphabet, SpaceX | Die Wall Street hat am Donnerstag schwächer tendiert. Der Dow Jones startete zunächst höher und legte zwischenzeitlich weiter zu, rutschte im Verlauf jedoch in die Verlustzone. Am Ende verlor der Leitindex... ► Artikel lesen | |
| PROGYNY | 31,910 | +0,16 % | KeyBanc raises Progyny stock price target on utilization strength | ||
| KESTRA MEDICAL TECHNOLOGIES | 24,420 | 0,00 % | Kestra Medical Technologies, Ltd.: Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing | KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it has entered... ► Artikel lesen | |
| GERRESHEIMER | 29,060 | +0,35 % | RAUS aus der Gerresheimer-Aktie? TKMS mit Kaufempfehlung! HPQ Silicon weckt Interesse! | Gerresheimer-Aktie verkaufen? Dazu raten Analysten. Dabei war nach den Bilanzierungsfragen, der verspäteten Vorlage des Geschäftsberichts, den Spekulationen rund um die BaFin-Prüfung sowie den Vorstandswechseln... ► Artikel lesen |